EZH2 and prostate cancer: Reduces ARs with the F876L mutation in DU-145 and C4–2 cells, and destroy prostate cancer stem/progenitor (S/P) cell invasion through the alteration of EZH2/STAT3 signaling in mice with CWR-22Rv1 CD133+ S/P xenografts.